AstraZeneca Breast-Cancer Drug Misses Goal in Late-Stage Trial

Live updates

1. 7h ago

   AstraZeneca Breast-Cancer Drug Misses Goal

   AstraZeneca PLC stated that its breast cancer pill Etcamah, also known as camizestrant, failed to meet the primary endpoint in the Phase III SERENA-4 trial. The trial tested the drug in combination with Pfizer's palbociclib as a first-line treatment for advanced ER-positive breast cancer. The stumble represents a significant setback for the pharmaceutical company's oncology pipeline. Market analysts suggest that missing this target could potentially reduce future sales projections by billions of dollars, adding to a history of setbacks for oral selective estrogen receptor degraders.

   Why it matters

   The Phase III SERENA-4 trial evaluated Etcamah combined with palbociclib in previously untreated patients with ER-positive, HER2-negative advanced breast cancer, recording only a numerical improvement rather than meeting its main goal. This outcome deals a blow to a drug considered a key growth opportunity within AstraZeneca's oncology portfolio. Oral selective estrogen receptor degraders have faced multiple setbacks across the pharmaceutical sector, complicating development paths for similar therapies.

   What is confirmed

   • AstraZeneca reported that its breast cancer pill Etcamah missed its primary endpoint in the Phase III SERENA-4 trial.
   • The trial evaluated Etcamah in combination with palbociclib as an upfront first-line treatment for advanced ER-positive, HER2-negative breast cancer.

   Still unconfirmed

   • The trial miss may trim billions of dollars from AstraZeneca sales.

   What to watch next

   • Further clinical data releases regarding the SERENA-4 trial
   • AstraZeneca corporate updates on the oncology pipeline and sales impact
   Sources used for this update (9)

   1. WSJ — AstraZeneca Breast-Cancer Drug Misses Goal in Late-Stage Trial
   2. astrazeneca.com — Update on SERENA-4 Phase III trial of Etcamah in combination with palbociclib in upfront 1st-line advanced ER-positive breast cancer
   3. STAT — Breast cancer pill from AstraZeneca misses mark in pivotal trial
   4. Fierce Pharma — AstraZeneca’s Etcamah flunks first-line breast cancer trial, adding to oral SERDs’ failure record
   5. Bloomberg.com — Astra Breast Cancer Pill Miss May Trim Billions From Sales
   6. FirstWord Pharma — AstraZeneca's oral SERD stumbles in Phase III first-line breast cancer trial
   7. jen.jiji.com — Food, Anir Confindustria: "For large-scale catering, more certainty on contracts and rules"
   8. jen.jiji.com — Ukraine, FBI's warning: "Russia plans targeted assassinations in the US and Europe"
   9. finance.yahoo.com — AstraZeneca’s Oncology Engine Faces a Key Test After Camizestrant Miss
   confidence 100%